These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28698985)

  • 21. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.
    Ciesek S; von Hahn T; Colpitts CC; Schang LM; Friesland M; Steinmann J; Manns MP; Ott M; Wedemeyer H; Meuleman P; Pietschmann T; Steinmann E
    Hepatology; 2011 Dec; 54(6):1947-55. PubMed ID: 21837753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus.
    Lee WP; Lan KL; Liao SX; Huang YH; Hou MC; Lan KH
    Am J Chin Med; 2018; 46(4):835-852. PubMed ID: 29737209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Procyanidin B1, a novel and specific inhibitor of Kv10.1 channel, suppresses the evolution of hepatoma.
    Na W; Ma B; Shi S; Chen Y; Zhang H; Zhan Y; An H
    Biochem Pharmacol; 2020 Aug; 178():114089. PubMed ID: 32533968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Procyanidin-B2 enriched fraction of cinnamon acts as a proteasome inhibitor and anti-proliferative agent in human prostate cancer cells.
    Gopalakrishnan S; Ediga HH; Reddy SS; Reddy GB; Ismail A
    IUBMB Life; 2018 May; 70(5):445-457. PubMed ID: 29537730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes.
    Haid S; Novodomská A; Gentzsch J; Grethe C; Geuenich S; Bankwitz D; Chhatwal P; Jannack B; Hennebelle T; Bailleul F; Keppler OT; Poenisch M; Bartenschlager R; Hernandez C; Lemasson M; Rosenberg AR; Wong-Staal F; Davioud-Charvet E; Pietschmann T
    Gastroenterology; 2012 Jul; 143(1):213-22.e5. PubMed ID: 22465429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry.
    Hsu WC; Chang SP; Lin LC; Li CL; Richardson CD; Lin CC; Lin LT
    Antiviral Res; 2015 Jun; 118():139-47. PubMed ID: 25865056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are statins a viable option for the treatment of infections with the hepatitis C virus?
    Verpaalen B; Neyts J; Delang L
    Antiviral Res; 2014 May; 105():92-9. PubMed ID: 24613180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection?
    Maggi F; Focosi D; Pistello M
    Curr Drug Targets; 2017; 18(7):811-825. PubMed ID: 26245474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Entry inhibitors and future treatment of hepatitis C.
    Fofana I; Jilg N; Chung RT; Baumert TF
    Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus.
    Chen C; Qiu H; Gong J; Liu Q; Xiao H; Chen XW; Sun BL; Yang RG
    Arch Virol; 2012 Jul; 157(7):1301-12. PubMed ID: 22491814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of protein glycation by procyanidin-B2 enriched fraction of cinnamon: delay of diabetic cataract in rats.
    Muthenna P; Raghu G; Akileshwari C; Sinha SN; Suryanarayana P; Reddy GB
    IUBMB Life; 2013 Nov; 65(11):941-50. PubMed ID: 24136906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel small-molecule inhibitor of hepatitis C virus replication acts by suppressing signal transducer and activator of transcription 3.
    Niu Y; Si Y; Li Y; Chi X; Li X; Liu X; Li D; Cheng M; Fan J; Si S; Yang W
    J Antimicrob Chemother; 2015 Jul; 70(7):2013-23. PubMed ID: 25858355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry.
    Chung CY; Liu CH; Wang GH; Jassey A; Li CL; Chen L; Yen MH; Lin CC; Lin LT
    Sci Rep; 2016 Jul; 6():29969. PubMed ID: 27426693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus entry.
    Zeisel MB; Felmlee DJ; Baumert TF
    Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoglycemic activities of A- and B-type procyanidin oligomer-rich extracts from different Cinnamon barks.
    Lu Z; Jia Q; Wang R; Wu X; Wu Y; Huang C; Li Y
    Phytomedicine; 2011 Feb; 18(4):298-302. PubMed ID: 20851586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.
    Syder AJ; Lee H; Zeisel MB; Grove J; Soulier E; Macdonald J; Chow S; Chang J; Baumert TF; McKeating JA; McKelvy J; Wong-Staal F
    J Hepatol; 2011 Jan; 54(1):48-55. PubMed ID: 20932595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries.
    Khan H; Paeshuyse J; Murad S; Neyts J
    Antiviral Res; 2016 Jan; 125():43-5. PubMed ID: 26593977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells.
    Liu S; Chen R; Hagedorn CH
    PLoS One; 2015; 10(7):e0131358. PubMed ID: 26186636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro.
    Hang X; Peng H; Song H; Qi Z; Miao X; Xu W
    J Virol Methods; 2015 Sep; 222():150-7. PubMed ID: 26116793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.